Abstract
In recent years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have emerged as promising options for weight management, offering not only glycemic control benefits but also significant reductions in body weight. Among these agents, Wegovy (semaglutide) and Ozempic (semaglutide) have gained attention for their efficacy in promoting weight loss, even in individuals without diabetes. However, the off-label use of these medications for weight management raises several questions and concerns regarding their safety, efficacy, and long-term effects. This comprehensive review aims to explore the complexities of GLP-1 agonists in weight management, focusing on their mechanism of action, clinical evidence, safety profile, dosing considerations, potential interactions, and future directions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pharmacy and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
